{"id":"NCT00968539","sponsor":"GlaxoSmithKline","briefTitle":"Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults","officialTitle":"Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09-08","primaryCompletion":"2010-09-28","completion":"2010-09-28","firstPosted":"2009-08-31","resultsPosted":"2017-12-18","lastUpdate":"2019-11-18"},"enrollment":130,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"GSK investigational vaccine GSK2340272A","otherNames":[]},{"type":"BIOLOGICAL","name":"GSK investigational vaccine GSK2340269A","otherNames":[]}],"arms":[{"label":"GSK2340272A GROUP","type":"EXPERIMENTAL"},{"label":"GSK2340269A GROUP","type":"EXPERIMENTAL"}],"summary":"The objective of the study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.","primaryOutcome":{"measure":"Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies","timeFrame":"At Day 42","effectByArm":[{"arm":"GSK2340272A Group","deltaMin":58,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":11,"exclusionCount":18},"locations":{"siteCount":1,"countries":["Belgium"]},"refs":{"pmids":["21450978","28446441"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":64},"commonTop":["Pain","Fatigue","Headache","Muscle aches","Sweating"]}}